--- title: "AstraZeneca rises 4% in after-hours on positive EU opinion for Baxfendy" type: "News" locale: "en" url: "https://longbridge.com/en/news/305514845.md" description: "AstraZeneca rose 3.82% to $191.50 in after-hours trading after Baxfendy won a positive EU regulatory opinion." datetime: "2026-11-13T23:41:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305514845.md) - [en](https://longbridge.com/en/news/305514845.md) - [zh-HK](https://longbridge.com/zh-HK/news/305514845.md) generator: "portal-rs" --- # AstraZeneca rises 4% in after-hours on positive EU opinion for Baxfendy AstraZeneca (AZN.US) rose nearly **4%** in after-hours trading to **$191.50**. The company's hypertension drug Baxfendy, also known as baxdrostat, received a positive regulatory opinion from an EU expert panel for adult patients whose blood pressure is not adequately controlled by at least two medications. If approved, it could become the first aldosterone synthase inhibitor in the European Union. Separately, AstraZeneca has completed its acquisition of bacterial vaccine biotechnology company Omniose, which is now a wholly-owned subsidiary of its vaccines and immune therapies unit. The deal integrates Omniose's proprietary bioconjugation platform to streamline the development of conjugate vaccines against multidrug-resistant superbugs. Meanwhile, at the ninth China International Import Expo, the company announced new progress on its 100 billion yuan investment commitment in China and showcased nearly 50 innovative medicines. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research - [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md) - [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md) - [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md) - [Revolution Medicines (RVMD) Reports Fresh RASONQUE Data, Is The Stock Priced For Perfection?](https://longbridge.com/en/news/306378335.md) - [Profit Outlook Raised Could Change The Case For Zeta Global Stock](https://longbridge.com/en/news/306379536.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**